<!DOCTYPE html>
<html>

<head>
    <title>GSK Master Template</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta name="format-detection" content="telephone=no" />
    <meta name="msapplication-tap-highlight" content="no" />
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />

    <link rel="stylesheet" href="../shared/css/jquery-ui.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="../shared/css/core.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="../shared/css/custom.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="../shared/css/presentation.css" type="text/css" charset="utf-8" />
    <link rel="stylesheet" href="css/local.css" type="text/css" charset="utf-8" />
</head>

<body>
    <div id="container" class="customSwipe">
        <!-- Left and right double click navigation -->
        <!--<div id="doubleClickRight" class="navBumper"></div>-->
        <!-- Portrait mode double click zoom -->
        <!--<div id="doubleClickCentre"></div>-->

        <!-- slide html -->
        <div class="mainContent" class="customSwipe">
            <div class="left_menu_1">
                <ul>
                    <li class="icon_6_active gotoSlide" data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN" data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_007"></li>
                    <li class="div_img"></li>
                    <li class="icon_7 gotoSlide" data-fields="TrackElementId|TrackElementDescription|TrackElementType" data-description="Exacerbation and OCS reduction (FR ATU)|Exacerbation and OCS use reduction (REALITI-A)|Animation" data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN" data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_008"></li>
                </ul>
            </div>
            <div class="pageHeading">Nucala: Associated with real-life<br>
                protection from exacerbations* and<br>
                maintenance OCS<sup>10</sup>
            </div>

            <div class="sub_head">
                FRANCE ATU<sup>10</sup>
            </div>

            <div class="box_1">
                <div class="arrow_img"></div>
                <div class="head_number"><span class="counti">86</span>%</div>
                <div class="head_text">REDUCTION IN EXACERBATIONS<br>
                    AT YEAR 2</div>
                <div class="para_text">
                    (n=75)<sup>10</sup><br>
                    5.8 ± 4.4 at baseline (over the previous 12 months)<br>
                    vs. 0.8 ± 1.1 (over the first 12 months after the first<br>
                    injection) and 0.8 ± 0.9 between 12 and 24 months
                </div>
            </div>


            <div class="box_2">
                <div class="head_number"><span class="counti1">65</span>%</div>
                <div class="people_img"></div>
                <div class="head_text">OF PATIENTS FREE FROM<br>
                    MAINTENANCE OCS AT YEAR 2</div>
                <div class="para_text">
                    (n=75)<sup>10</sup><br>
                    n=49/75 (65.3%) at 24 months
                </div>

                
                <div class="p1_img"></div>
                <div class="plus_icon gotoSlide" data-fields="TrackElementId|TrackElementDescription|TrackElementType" data-description="Exacerbation and OCS reduction (FR ATU)|Patient - Frequent exacerbations|Popup" data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN" data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_001.1"></div>

                <div class="p2_img"></div>
                <div class="plus_icon_1  gotoSlide" data-fields="TrackElementId|TrackElementDescription|TrackElementType" data-description="Exacerbation and OCS reduction (FR ATU)|Patient - OCS dependent|Popup" data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN" data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_001.3"></div>
            </div>

            <div class="summ_content">
                <div class="text_summ">Real-world studies are designed to evaluate associations among variables and not
                    to definitively
                    establish causality. These limitations are important when interpreting results: lack of comparator
                    arm,
                    differences in patient populations and data collection vs. randomised controlled trials.<br>
                    France ATU is a retrospective observational study.</div>
                <div class="head_summ">Results are descriptive.</div>

            </div>




            <div class="foot_t">
                <p>ATU, Temporary Authorisation for Use; ED, emergency department; OCS, oral corticosteroid; RA,
                    REALITI-A<br>
                    In the 24-week Phase III study, SIRIUS, the secondary outcome of total cessation in OCS use was not
                    significant (N (%);<br>Nucala 10/69 (14%) vs. 5/66 (8%)<br>
                    placebo <em>p</em>=0.41).<sup>7</sup> However, the protocol did not allow for patients on higher doses (25mg/day or
                    more) to be weaned completely<br>
                    *Defined as deterioration in asthma requiring use of systemic corticosteroids and/or an ED visit
                    and/or hospital admission</p>

            </div>

        </div>

        </div>
        <!-- <div class="zincCode">
            XX/XX/0000/00
        </div><br />
        <div class="preparation">
            Date of Preparation: April 2019
        </div> -->
        <!-- end of slide html -->

        <!-- mtgsk html -->
        <div class="logo_top"></div>
        <!-- <div class="header">
            <div class="mainLogo" id="logo"></div>
        </div> -->
        <div class="footer">
            <div class="brandLogo" id="footerLogo"></div>
        </div>

        <div class="button_b2 openDialog" data-fields="TrackElementId|TrackElementDescription|TrackElementType" data-description="Exacerbation and OCS reduction (FR ATU)|France ATU Study design|Animation"  data-dialog="#dialog">FRANCE ATU STUDY DESIGN AND<br>
            BASELINE CHARACTERISTICS</div>
        <div class="navBottom">
            <div id="home" class="gotoSlide"></div>
            <!-- <div id="menu" class="gotoSlide logEmbedded" data-description="Embedded Menu"></div> -->
            <div id="pi" class="gotoSlide logEmbedded" data-description="Embedded PI"></div>
            <div id="references" class="gotoSlide logEmbedded" data-description="Embedded References"></div>
            <div id="email"></div>
            <div id="summary" class="gotoSlide logEmbedded display" data-presentation="Nucala_eDetail_Bridge_campaign_2020_MF1.0_MAIN" data-slide="Nucala_eDetail_Bridge_campaign_2020_MF1.0_013" ></div>
            <div id="objection" class="gotoSlide logEmbedded" data-description="Embedded Objections"></div>
            <div id="resource" class="gotoSlide logEmbedded display" data-presentation="Nucala_Edetail_Real_Life_2020_MF1.0_MAIN" data-slide="Nucala_Edetail_Real_Life_2020_MF1.0_RES" ></div>
            <div id="quickres" class="gotoSlide logEmbedded" ></div>
        </div>
        <!-- end mtgsk html -->




        <div id="dialog" class="dialog hidden" data-width="2048" data-height="100" data-description="Parent popup">
            <div class="title_practice">France ATU: Study design and<br>
                baseline characteristics</div>
            <div class="popup_content">
                <div id="section_1">
                    <div class="content_1">
                        DESCRIPTION<sup>10</sup>
                        <p>Observational and retrospective study to collect long-term, follow-up, real-life data from
                            the first patients treated with NUCALA in France within nominative ATU.</p>
                    </div>
                    <div class="content_1">
                        OBJECTIVES<sup>10</sup>
                        <p>Primary objective: describe the profile of the patients included in the nominative ATU.
                            Secondary objective: describe up to 24 months of the disease evolution and treatment
                            changes in the patients included within nominative ATU. These data were analysed with
                            a before/after comparison between the inclusion and the follow-up at 24 months.</p>
                    </div>
                    <div class="content_1">
                        STUDY POPULATION, N=146<sup>10</sup>
                        <p>All patients included in the nominative ATU between 9 June 2015 and 2 March 2016.</p>
                    </div>

                    <div class="down_arrow shake-bottom"></div>
                </div>

                <div id="section_2">
                    <div class="up_arrow shake-top"></div>
                    <div class="content_2">
                        SAFETY POPULATION, N=147<sup>10</sup>
                        <p>In total, 41 patients discontinued NUCALA. The most frequent
                            reasons leading to discontinuation were lack of efficacy (29 patients),
                            asthma (10 patients), headaches (6 patients) and asthenia
                            (5 patients). There were 14 serious adverse events reported.
                            The most common serious adverse event was asthma (n=3).</p>
                    </div>
                    <div class="foot_text">
                        ACT, asthma control test; AERD; aspirin exacerbated respiratory disease; ATU, Temporary
                        Authorisation for Use; BMI, body mass index; FEV<sub>1</sub> forced expiratory volume in one second;
                        GERD, gastroesophageal reflux disease; OCS, oral corticosteroid; SD, standard deviation<br>
                        *n=137; **n=145; <sup>†</sup>n=128; <sup>††</sup>n=134; <sup>‡</sup>n=62; <sup>‡‡</sup>n=142;
                        <sup>§</sup>n=130; <sup>§§</sup>n=136; <sup>#</sup>n=135
                    </div>

                    <div class="right_content">
                        <table class="tg">
                            <tr>
                                <th class="tg-g59i" colspan="2">SUMMARY OF BASELINE
                                        CHARACTERISTICS<sup>10</sup></span></th>
                            </tr>
                            <tr>
                                <td class="tg-xogg"></td>
                                <td class="tg-xogg"><span style="font-weight:bold">Total population (N=147)</span></td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Age in years, mean (SD)</td>
                                <td class="tg-0pky">58.2 (13,6)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Female, n (%)</td>
                                <td class="tg-0pky">66 (45.2)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">BMI, kg/m<sup>2</sup>, mean (SD)*</td>
                                <td class="tg-0pky">27.2 (5.1)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">BMI ≥ 30 kg/m<sup>2</sup>, n (%)*</td>
                                <td class="tg-0pky">32 (23.4)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Smoking history**<br>Current smoker, n (%) <br>Former smoker, n (%)
                                    <br>Pack/year, mean (SD)</td>
                                <td class="tg-0pky">
                                   <ul>
                                       <li></li>
                                       <li>11 (7.6)</li>
                                       <li>57 (39.3)</li>
                                       <li>17.8 (14.9)</li>
                                   </ul>
                                </td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Duration of severe asthma, years (SD)<sup>†</sup></td>
                                <td class="tg-0pky">13.4 (12.1)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Number of exacerbations in the previous year,<br>mean (SD)<sup>††</sup></td>
                                <td class="tg-0pky">5.8 (4.4)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Mean ACT score (SD)<sup>‡</sup></td>
                                <td class="tg-0pky">10.2 (4.5)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">FEV<sub>1</sub>%, mL (SD)<sup>‡‡</sup></td>
                                <td class="tg-0pky">1883.0 (823.2)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">FEV<sub>1</sub>, % of predicted value (SD)<sup>‡‡</sup></td>
                                <td class="tg-0pky">62.0 (19.4)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Blood eosinophil count, cells/μL (SD)<sup>§</sup></td>
                                <td class="tg-0pky">721.7 (500.0)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Patients on maintenance OCS, %<sup>§§</sup></td>
                                <td class="tg-0pky">92.8</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Mean dose at inclusion, mg/day (SD)<sup>#</sup></td>
                                <td class="tg-0pky">20.6 (16.5)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Previous treatment with omalizumab, n (%)</td>
                                <td class="tg-0pky">91 (65.9)</td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Co-morbidities, n (%)<br>Nasal polyps <br>GERD <br>Osteoporosis
                                    <br>Cardiovascular disease <br>AERD</td>
                                <td class="tg-0pky">
                                    <ul>
                                        <li>137 (93.8)</li>
                                        <li>53 (38.7)</li>
                                        <li>53 (38.7)</li>
                                        <li>51 (37.2)</li>
                                        <li>48 (35.0)</li>
                                        <li>22 (16.1)</li>
                                    </ul>
                                </td>
                            </tr>
                            <tr>
                                <td class="tg-0pky">Allergies, n (%)</td>
                                <td class="tg-0pky">62 (42.5)</td>
                            </tr>
                        </table>
                    </div>

                </div>
            </div>
        </div>




    </div>
    <!-- Background settings required for pdf style portrait mode zoom -->
    <div class="bg" id="bg"></div>
    <script src="../shared/js/jquery-3.1.0.min.js"></script>
    <script src="../shared/js/jquery-ui.js"></script>
    <script src="../shared/js/jquery.ui.touch-punch.js"></script>
    <script src="../shared/js/veeva-library.js"></script>
    <script src="../shared/js/config.json"></script>
    <script src="../shared/js/fastclick.min.js"></script>
    <script src="../shared/js/hammer.min.js"></script>
    <script src="../shared/js/iscroll.js"></script>
    <script src="../shared/js/mt.js"></script>
    <script src="../shared/js/presentation.js"></script>
    <script src="../shared/js/race.js"></script>
    <script src="js/local.js"></script>
    <!-- <script src="../shared/posChanger-3.4.js"></script>
    <script src="../shared/specific.js"></script> -->
</body>

</html>